DBV Technologies (DBVT) Net Income towards Common Stockholders (2014 - 2026)
DBV Technologies (DBVT) reported Net Income towards Common Stockholders of -$47.6 million for Q1 2026, down 75.65% year-over-year from -$195.4 million in Q1 2025, and down 6.18% on a QoQ basis from -$44.8 million in Q4 2025.
DBV Technologies (DBVT) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$47.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 75.65% year-over-year to -$47.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$167.5 million (down 47.32% YoY) and the FY2025 annual result came in at -$146.9 million, down 28.99% from the prior year.
- Net Income towards Common Stockholders slipped to -$47.6 million in Q1 2026 per DBVT's latest filing, from -$44.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$11.2 million in Q4 2023 and bottomed at -$47.6 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$27.1 million (2025), against an average of -$28.1 million.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders plunged 187.02%; it then soared 71.49% in 2023.
- Tracing DBVT's Net Income towards Common Stockholders over 5 years: stood at -$39.2 million in 2022, then soared by 71.49% to -$11.2 million in 2023, then slumped by 105.75% to -$23.0 million in 2024, then slumped by 94.78% to -$44.8 million in 2025, then slipped by 6.18% to -$47.6 million in 2026.
- Per Business Quant, the three latest DBVT Net Income towards Common Stockholders figures stand at -$47.6 million (Q1 2026), -$44.8 million (Q4 2025), and -$33.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | -47.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -44.83 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.88 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.02 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.24 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.24 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -13.67 Mn |
| Sep 30, 2021 | -24.03 Mn |
| Jun 30, 2021 | -30.65 Mn |
| Mar 31, 2021 | -29.45 Mn |
| Dec 31, 2020 | -39.49 Mn |
| Sep 30, 2020 | -30.96 Mn |
| Mar 31, 2020 | -40.91 Mn |
| Sep 30, 2019 | -131.31 Mn |
| Dec 31, 2018 | -57.75 Mn |
| Sep 30, 2018 | -50.49 Mn |
| Jun 30, 2016 | -55.21 Mn |
| Dec 31, 2015 | -16.35 Mn |
| Jun 30, 2015 | -15.81 Mn |
| Dec 31, 2014 | -15.10 Mn |
| Jun 30, 2014 | -16.08 Mn |